Minims Cyclopentolate Chlorhydrate Bausch + Lomb Ireland Limited (Cyclopentolate Hydrochloride)

Cyclopentolate Hydrochloride is used in ophthalmology to achieve controlled pupil dilation and temporary loss of accommodation.

• Pupil dilation for ophthalmic examinations: provides reliable mydriasis to allow thorough retinal and optic nerve evaluation.
• Cycloplegia for accurate refraction: temporarily paralyzes the ciliary muscle to enable precise measurement of refractive errors.
• Adjunct in the management of anterior uveitis: helps reduce iris spasm and facilitates assessment of intra‑ocular inflammation.

• Cyclopentolate Hydrochloride acts as a competitive antagonist at muscarinic acetylcholine receptors in the iris sphincter and ciliary body. By blocking these receptors, it prevents parasympathetic-mediated contraction, leading to relaxation of the sphincter muscle (mydriasis) and inhibition of the ciliary muscle (cycloplegia), thereby facilitating ocular examinations and refraction.

Cyclopentolate eye drops may cause a range of ocular and systemic reactions.

Common Side Effects

• Stinging or burning sensation upon instillation
• Transient blurred vision
• Photophobia due to prolonged pupil dilation
• Mild increase in intra‑ocular pressure
• Temporary conjunctival redness

Serious or Rare Side Effects

• Allergic reaction (rash, swelling, itching)
• Persistent mydriasis lasting several days
• Acute angle‑closure glaucoma
• Severe ocular inflammation or uveitis flare
• Systemic anticholinergic effects such as dry mouth or tachycardia

Before prescribing Cyclopentolate, clinicians should evaluate ocular and systemic risk factors.

• Intra‑ocular pressure assessment: measure baseline pressure to detect narrow‑angle glaucoma risk.
• Contraindicated in known narrow‑angle or acute angle‑closure glaucoma.
• Use cautiously in patients with systemic anticholinergic sensitivity (e.g., urinary retention, prostatic hypertrophy).
• Avoid concurrent use with miotic agents unless specifically directed.
• Pregnancy and breastfeeding: safety not established; weigh potential benefits against unknown risks.
• Store at room temperature: keep in original container, protect from light and moisture.

Cyclopentolate may interact with other ocular or systemic agents, altering efficacy or safety.

Major Interactions (Avoid)

• Other anticholinergic medications: additive systemic anticholinergic effects.
• Miotic agents (e.g., pilocarpine): antagonistic action reducing mydriasis.
• Systemic adrenergic drugs that raise intra‑ocular pressure.

Moderate Interactions (Monitor Closely)

• Topical anesthetics: may increase corneal absorption of cyclopentolate.
• Beta‑blocker eye drops: monitor intra‑ocular pressure changes.
• Systemic antihistamines: potential enhancement of anticholinergic load.